Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT (GlobeNewswire) - Jun 7, 2024 - "Currently utilized in the CPRIT-funded ReSPECT-LM clinical trial, CNSide is on track for commercial launch as soon as Q4 2024....Furthermore, the Company also received notice of a $3.3 million advance grant payment from CPRIT in June 2024. This funding supports the clinical development of rhenium (Re186) obisbemeda for LM as well as CNSide testing in the RePSECT-LM trial. In addition to determining the safety and potential efficacy of rhenium (Re186) obisbemeda for LM, data gathered from the RePSECT-LM trial will further validate CNSide's clinical utility and support commercialization. An update on enrollment and safety data from the ReSPECT-LM trial is planned for the August SNO/ASCO Meeting in Denver."
Diagnostic • Financing • Launch • P1 data • Brain Cancer • CNS Tumor • Oncology • Solid Tumor
|